Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00356031 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and Radiation Therapy for Sarcomas
A Phase 2 study of Soft Tissue Sarcoma and Leiomyosarcoma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00356031: Completed Phase 2 study of Soft Tissue Sarcoma and Leiomyosarcoma, sponsored by Massachusetts General Hospital.
NCT00356031 is a Phase 2 study of Soft Tissue Sarcoma and Leiomyosarcoma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00356031, a Phase 2 study of Soft Tissue Sarcoma and Leiomyosarcoma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to test the effectiveness of bevacizumab in combination with radiation therapy to see what effects (good or bad) they have on patients with soft tissue sarcoma. Bevacizumab is an antibody designed specifically to slow or stop the growth of cancerous tumors by decreasing the blood supply to the tumor. Bevacizumab is approved by the FDA in combination with intravenous 5-fluorouracil-based chemotherapy as a treatment for patients with cancer of the colon or rectum that has spread. However, the use of bevacizumab in combination with radiation for sarcomas is still under investigation.
Primary Outcome
The count of participants with greater than or equal to 80% pathological necrosis in the resected specimen following neoadjuvant bevacizumab and radiation.
Conditions Studied
Interventions
- DRUG Bevacizumab
- RADIATION Radiation Therapy
- PROCEDURE Surgery
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
What the finished NCT00356031 record still lists
NCT00356031 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (75% lower).
The record links to 6 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00356031 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00356031 about?
NCT00356031 is a clinical study titled "Bevacizumab and Radiation Therapy for Sarcomas". The main purpose of this study is to test the effectiveness of bevacizumab in combination with radiation therapy to see what effects (good or bad) they have on patients with soft tissue sarcoma. Bevacizumab is an antibody designed specifically to slow or stop the growth of cancerous tumors by decrea...
What is the current status of trial NCT00356031?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2006-07. Estimated completion is 2010-03.
What conditions does trial NCT00356031 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma, Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Fibrosarcoma.
What interventions are being tested in trial NCT00356031?
The interventions under investigation include: Bevacizumab (DRUG), Radiation Therapy (RADIATION), Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00356031?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00356031 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00356031's enrollment target sits among peer trials
20 47th of 55 higher than 9 of 55 other Soft Tissue Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
RECRUITING · Phase 2
-
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
RECRUITING · Phase 2
-
5-Day Preoperative Radiation for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia